|
| |
| | | 00558 | | 03.09.1993 | | GlaxoSmithKline AG | | | | | | | | | | | | | 08.08. | | | | 08.08. | | IP |
| | Seq.-No. | Product | Description | Galenic form | ATC-classification | |
|---|
| 01 | Havrix 1440 | | Suspension () | J07BC02 | | | 02 | Havrix 1440 | Injektionssuspension | Injection suspension (Hepatitis-A-Virus Inactivatus (Hm175) 1440 U/ml) | J07BC02 | | | 03 | Havrix 1440 | | (Vaccinum Hepatitidis a Inactivatum Adsorbatum 1440 U) | | |
|
|
|
